Allergen Announces Acquisition of Bonti for its Two Aesthetic and Therapeutic Products

 Allergen Announces Acquisition of Bonti for its Two Aesthetic and Therapeutic Products

Allergen Announces Acquisition of Bonti for its Two Aesthetic and Therapeutic Products

Shots:

  • On Completion of Acquisition Allergen will have global rights to EB-001A (aesthetic) and EB-001T (therapeutic) program currently under P-II trial
  • Allergen will pay an upfront payment of $195M to Bonti addition to potential commercial milestone payments
  • The focus of the acquisition is EB-001, a novel botulinum neurotoxin serotype E (BoNT/E), with rapid onset of action in 24 hours and 2 to 4-week duration effect for medical aesthetics treatment

Click here to read full press release/ article | Ref: Allergen | Image: Bloomberg

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post